ALK to present positive phase II data on its tablet for the treatment of peanut allergy at ACAAI 2026
ALK will present phase II data from the ALLIANCE trial of its once-daily investigational sublingual immunotherapy (SLIT) tablet for peanut allergy1,2,3 at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona from 12 to 16 November 2026. The trial included 150 patients aged 4–65 years and evaluated two doses of the tablet compared with placebo.
Covered in this story
Call it yourself
No calls on $ALK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alaska Air Group →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.